3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
31
Leukemia, Myeloid, Chronic-Phase
12
Leukemia
6
Gastrointestinal Stromal Tumors
6
Neoplasm Metastasis
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Melanoma
3
Synovitis, Pigmented Villonodular
2
Recurrence
2
Ovarian Neoplasms
2
Hematologic Diseases
2
Blast Crisis
2
Substance Withdrawal Syndrome
1
Peritoneal Neoplasms
1
Neoplastic Processes
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Mucosal Lentiginous Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Glioma
1
Giant Cell Tumor of Tendon Sheath
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
simtuzumab
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
ibrutinib
1
SCIO-469
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bone Marrow Diseases
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA